Reviva Pharmaceuticals Holdings Inc. Warrants (25/12/2025) RVPHW 深 沪
等待开盘 05-19 09:30:00 美东时间
0.003
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.003
- 总市值 2.77万
- 52周最高 0.3678
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.003
- 委 比 0.00%
- 总股本 923.17万
- 历史最高 3.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.003
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Reviva Pharmaceuticals Q1 EPS $(0.46) Beats $(0.62) Estimate
Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.62) by 25.81 percent. This is a 82.31 percent increase over losses of $(2.60) per share
05-14 04:39
Reviva Pharmaceuticals To Be Delisted From Nasdaq On May 14
As previously disclosed, the common stock of Reviva Pharmaceuticals Holdings, Inc. (the "Company") was not in compliance with the requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement") to maintain
05-13 20:28
Reviva Pharmaceuticals Holdings Inc <RVPH.OQ> expected to post a loss of 62 cents a share - Earnings Preview
Reviva Pharmaceuticals Holdings Inc expected to post a loss of 62 cents a share - Earnings Preview Reviva Pharmaceuticals Holdings Inc RVPH.OQ RVPH.O is expected to show no change in quarterly revenue when it reports results on May 13 (estimated) for the period ending March 31 2026 LSEG's mean an
05-11 19:36
Reviva Updates Brilaroxazine Strategy and Funding Outlook
Reviva Pharmaceuticals Holdings ( ($RVPH) ) just unveiled an announcement. On A...
04-15 20:28
Reviva Pharmaceuticals Holdings Says Aims To Extend Brilaroxazine Patent Life And Exclusivity Potentially Through 2046; To Initiate Trial Activities In Q2 2026, Begin Enrollment In Q3 2026, For RECOVER-2; Preparing To Seek FDA Alignment On New Form Of Brilaroxazine For NDA
Regulation FD Disclosure.On April 15, 2026, Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") issued a letter to shareholders announcing certain business updates, including in connection with the
04-15 20:16
Maxim Group Downgrades Reviva Pharmaceuticals to Hold
Maxim Group analyst Jason McCarthy downgrades Reviva Pharmaceuticals (NASDAQ:RVPH) from Buy to Hold.
04-08 21:20
BRIEF-Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights
BRIEF-Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights March 30 (Reuters) - Reviva Pharmaceuticals Holdings Inc RVPH.O : REVIVA REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS REVIVA PHARMACEUTICALS FY NET INCOME USD -19.9 MILLION REVIVA PHARMACE
03-30 21:57
Reviva Pharmaceuticals Q4 EPS $(0.57) Misses $(0.10) Estimate
Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.10) by 455.88 percent. This is a 81.1 percent increase over losses of $(3.00) per
03-30 19:57
Reviva FY25 net loss narrows 33.61% to $19.9 million
Reviva FY25 net loss narrows 33.61% to $19.9 million Reviva posted a full-year net loss of $19.9 million, narrowing from $29.9 million. Operating loss tightened to $20.2 million as research and development expense fell to $11.7 million. Cash and cash equivalents ended the year at $14.4 million. FDA
03-30 18:05
Reviva Pharmaceuticals Holdings Inc <RVPH.OQ> expected to post a loss of $1.17 a share - Earnings Preview
Reviva Pharmaceuticals Holdings Inc expected to post a loss of $1.17 a share - Earnings Preview Reviva Pharmaceuticals Holdings Inc RVPH.OQ RVPH.O is expected to show no change in quarterly revenue when it reports results on March 30 (estimated) for the period ending December 31 2025 LSEG's mean
03-27 20:27
